TabsDetailsBasic DetailsDate Posted: Monday, March 12, 2018Status: CompleteMedical Product: bendamustine, bortezomib, chlorambucil, cyclophosphamide, doxorubicin, ibritumomab, ibrutinib, idelalisib, lenalidomide, obinutuzumab, ofatumumab, prednisone, rituximab, vincristineDescription: This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use. Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016. Read More Deliverables (1)Sentinel Modular Program Report: Concomitancy and Indications for Idelalisib UseAdditional InformationAdditional DetailsFDA Center: CDERTime Period: July 23, 2014 - December 31, 2015Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Individuals 18 years of age and olderData Sources: Sentinel Distributed Database (SDD)
